Management of cytomegalovirus corneal endotheliitis

作     者：Angela H.Y.Wong Wee Nie Kua Alvin L.Young Kelvin H.Wan 

作者机构：Department of OphthalmologyTuen Mun HospitalHong KongChina Department of Ophthalmology and Visual SciencesPrince of Wales HospitalHong KongChina Department of Ophthalmology and Visual SciencesThe Chinese University of Hong KongHong KongChina 

出 版 物：《Eye and Vision》 (眼视光学杂志（英文）)

年 卷 期：2021年第8卷第1期

页      面：18-30页

核心收录：

学科分类：1204[管理学-公共管理] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100212[医学-眼科学] 10[医学] 

主　　题：Cytomegalovirus CMV Endotheliitis Keratoplasty Corneal transplant Cornea 

摘      要：Background:Cytomegalovirus(CMV)can manifest as corneal endotheliitis in immunocompetent *** diagnosis is prudent to prevent endothelial cell loss,which could ultimately lead to corneal *** DNA was first detected in an eye with corneal endotheliitis in 2006;since then,clinical evidence from numerous case reports and case series have *** text:In this narrative review,we identified several drugs,including ganciclovir,valganciclovir,and their combination in oral,intravenous,intravitreal,and topical forms in different concentrations,together with the judicious use of topical steroids,have reported variable *** has yet to be any prospective comparative study evaluating the efficacy and safety of these assorted forms of treatment;clinical evidence is based on case reports and case *** endotheliitis presenting with corneal edema can masquerade as other corneal diseases and thus poses a great challenge especially in post-keratoplasty *** awareness is needed before and after keratoplasty to start prompt prophylaxis and ***:There is no consensus on the management of CMV *** studies are much needed to elucidate the optimal treatment modality,regime,and duration in the treatment and prophylaxis of CMV endotheliitis.